<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydroxyurea use in sickle cell disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydroxyurea use in sickle cell disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hydroxyurea use in sickle cell disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Griffin P Rodgers, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alex George, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Strouse, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The major causes of morbidity and mortality in sickle cell disease (SCD) are the acute and long-term consequences of vaso-occlusion and hemolysis, many of which cannot be reversed (eg, tissue infarction, vasculopathy). </p><p>The approaches that are available for reducing these pathophysiologic processes are regular red blood cell (RBC) transfusions, medications (<a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, L-glutamine, <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">voxelotor</a>, and <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">crizanlizumab</a>) and stem cell therapies (hematopoietic cell transplantation [HCT] and gene therapy).</p><p>This topic review discusses <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy in SCD, including the mechanism of action, administration, dosing, and adverse effects. </p><p>Separate topic reviews discuss the following subjects:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of pain – (See  <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">"Evaluation of acute pain in sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of pain – (See  <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Transplant – (See  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Investigational therapies – (See  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Overview of management – (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Routine care for children – (See  <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Transition from pediatric to adult care – (See  <a class="medical medical_review" href="/z/d/html/112919.html" rel="external">"Sickle cell disease (SCD) in adolescents and young adults (AYA): Transition from pediatric to adult care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>RBC transfusions – (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p></p><p>The choice of preventive therapy in patients with specific complications such as acute chest syndrome (ACS) or stroke is also presented separately. (See  <a class="medical medical_review" href="/z/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> has been in use for decades, first approved by the US Food and Drug Administration (FDA) in 1967 as an antineoplastic drug for the treatment of multiple cancers (melanoma, ovarian cancer, myeloproliferative neoplasms) and then for adults with SCD in 1998. It was approved for pediatric use in SCD as a specific formulation in 2017 but has been used in children with SCD for decades. Despite this long experience, understanding of the mechanism of action of hydroxyurea in SCD remains incomplete [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2514106759"><span class="h2">Inhibition of ribonucleotide reductase</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> can bind metals. Its primary cellular target is the ribonucleotide reductase enzymes, iron-containing enzymes that convert ribonucleoside diphosphates to deoxyribonucleotide triphosphates (dNTPs), which are used in DNA (deoxyribonucleic acid) synthesis and repair [<a href="#rid2">2,3</a>]. </p><p>Ribonucleotide reductases use a free radical mechanism to catalyze the conversion to dNTPs, and <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> appears to block their function by binding the iron molecules and scavenging the free radicals [<a href="#rid4">4</a>]. The lack of available dNTPs causes cells to arrest in S-phase of the cell cycle. Eventually, cells with stalled DNA replication forks will either delay S-phase until DNA synthesis can proceed, or they will undergo cell death.</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> has been shown to suppress other enzymes such as iron-sulfur cluster-containing enzymes (see  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Iron-sulfur (Fe-S) cluster biogenesis'</a>), but it is not clear whether there is any physiologic effect in vivo.</p><p>Because <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> affects cell division, it causes global myelosuppression, including neutropenia, anemia, and thrombocytopenia. (See <a class="local">'Myelosuppression'</a> below.)</p><p class="headingAnchor" id="H543179326"><span class="h2">Increased Hb F production</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> causes a shift in gene expression at the beta globin locus, such that expression from the gamma globin locus is increased relative to that from the beta globin locus. This results in increased production of fetal hemoglobin (Hb F; α<sub>2</sub>γ<sub>2</sub>) and decreased production of adult hemoglobin (Hb A; α<sub>2</sub>β<sub>2</sub>), the reverse of the normal fetal switch. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hemoglobin switching and downregulation of Hb F expression'</a>.)</p><p>Since the gamma globin chain is not affected by the sickle mutation, the overall effect in patients with SCD is to reduce the relative concentration of hemoglobin S (Hb S; α<sub>2</sub>β<sup>S</sup><sub>2</sub>).</p><p>Hb F is the hemoglobin normally produced during fetal development and early infancy. Hb F has properties that differ slightly from Hb A (eg, slightly higher oxygen affinity), but it is well tolerated and causes no clinical problems. <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> increases Hb F production at least twofold above baseline, often much more. The concentration of Hb F per cell, the proportion of Hb F-containing cells, and the overall percentage of Hb F are all increased. The resultant decrease in the relative intracellular concentration of Hb S leads to less hemoglobin polymerization and precipitation. (See  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Hb polymerization'</a>.)</p><p>These effects reduce the formation of sickled red blood cells (RBCs). RBC lifespan is increased; hydration is improved, hemolysis is reduced, and adhesion to the vascular endothelium is lessened [<a href="#rid5">5-9</a>]. In turn, blood flow through the microcirculation improves and vaso-occlusive events are less likely to occur. This is thought to be the major mechanism by which <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> reduces vaso-occlusive events. </p><p>Supporting evidence includes:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective observational study of 230 children with SCD who were treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, Hb F &gt;20 percent was associated with much lower rates of hospitalization, vaso-occlusive pain, acute chest syndrome, and fever [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observational studies of individuals with naturally higher Hb F levels and mouse models suggest a role for Hb F [<a href="#rid11">11-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease"</a>.)</p><p></p><p>The mechanism(s) by which <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> increases Hb F production are incompletely understood and may include epigenetic modification, gene transcription, and cell signaling [<a href="#rid16">16</a>]. Increased nitric oxide (NO) levels and cyclic nucleotides such as guanylyl cyclase may induce Hb F transcription via genes that regulate globin gene transcription and translation, including BCL11A, a key regulator of baseline Hb F levels [<a href="#rid17">17-19</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'BCL11A'</a>.)</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may induce expression of the small GTP-binding protein (G protein) SAR1 (<strong>s</strong>ecretion-<strong>a</strong>ssociated and <strong>r</strong>as-related signaling protein), which activates gamma globin expression through c-Jun N-terminal kinase (JNK/Jun) [<a href="#rid20">20,21</a>]. Expression is increased from the G-gamma rather than the A-gamma gene [<a href="#rid22">22</a>]. These effects require active erythropoiesis, which may be suppressed by transfusion and possibly increased by erythropoietin. Alternative approaches to increasing Hb F production via these pathways are under investigation. (See  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Increasing Hb F'</a>.)</p><p>The changes in Hb F and Hb S production are first seen in reticulocytes. It may take up to three or more weeks to be seen in mature RBCs and up to six months to affect clinical symptoms. The effects are completely reversible upon drug discontinuation, necessitating lifelong therapy in most cases. (See <a class="local">'Can therapy be discontinued?'</a> below.)</p><p class="headingAnchor" id="H373440746"><span class="h2">Other mechanisms</span><span class="headingEndMark"> — </span>While reduced sickling due to increased Hb F levels is a major beneficial effect of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in SCD, other mechanisms may also play a role:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitric oxide</strong> – <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may increase NO levels by two mechanisms. Free hemoglobin, released during hemolysis, is a natural NO scavenger. Hydroxyurea reduces hemolysis and in turn may reduce free hemoglobin, allowing NO levels to be higher. Intracellularly, hydroxyurea leads to NO production in RBCs and endothelial cells via multiple mechanisms including direct NO generation by reacting with heme proteins [<a href="#rid23">23-27</a>]. NO is a potent vasodilator, and depletion in certain vascular beds could contribute to vaso-occlusion; increases in NO may improve blood flow in certain beds such as the pulmonary vasculature [<a href="#rid17">17,23-26,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC rheology</strong> – The lower reticulocyte count and corresponding shift to more mature RBCs may improve RBC volume, density, adhesivity, and passage through the microcirculation independent of Hb F levels [<a href="#rid9">9,29-32</a>]. This may be due in part to a reduction in the proportion of reticulocytes and young, low-density RBCs, which are particularly likely to adhere to vascular endothelium [<a href="#rid29">29,33</a>]. Effects of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> on cellular signaling pathways may also reduce adhesion [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Effects on the RBC'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>White blood cells </strong>– Reduced white blood cell (WBC) counts and/or neutrophil adhesivity to the vascular endothelium may reduce vaso-occlusion [<a href="#rid34">34</a>]. In vitro studies have shown that neutrophils from individuals with SCD have enhanced binding to fibronectin and increased activation [<a href="#rid35">35,36</a>]. In a trial that randomly assigned individuals with SCD to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> or placebo, lower neutrophil counts were associated with fewer pain episodes during two years of observation [<a href="#rid37">37</a>]. In contrast, an inverse relationship between Hb F-containing cells and pain episodes was only seen during the first three months of the trial. Interpretation is difficult because the hydroxyurea dose was titrated to the neutrophil count. (See  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Inflammation'</a>.)</p><p></p><p class="headingAnchor" id="H2305724976"><span class="h2">Predictors of response</span><span class="headingEndMark"> — </span>The Hb F response to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is variable and complex; there is no specific feature that can be used to determine whether an individual treated with hydroxyurea will obtain a clinical benefit or the magnitude of the benefit. Even children with low baseline percent Hb F levels can develop substantial increases in Hb F when treated at maximally tolerated doses [<a href="#rid38">38</a>]. Thus, hydroxyurea is offered to all individuals who could potentially benefit from it. (See <a class="local">'Indications and appropriate age to start therapy'</a> below.)</p><p>Predictors of response to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> were explored in a subset of children who participated in the HUG-KIDS study, in which hydroxyurea was administered to children between 5 and 15 years of age and titrated to a maximum tolerated dose [<a href="#rid38">38</a>] (see <a class="local">'Monitoring and dose titration'</a> below). For the 53 children who were treated at maximum tolerated dose for at least a year, the following characteristics predicted the greatest increase in percentage of Hb F, typically used as a surrogate for clinical efficacy:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline percent Hb F</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline WBC count</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline hemoglobin concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Higher maximally tolerated dose of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a></p><p class="bulletIndent1"><span class="glyph">●</span>Better compliance (fewer unused pills returned at follow-up)</p><p class="bulletIndent1"><span class="glyph">●</span>Greater treatment-related increases in hemoglobin and mean corpuscular volume (MCV)</p><p class="bulletIndent1"><span class="glyph">●</span>Greater treatment-related decreases in WBC count and reticulocyte count</p><p></p><p>Baseline Hb F percentages were approximately 4 to 8 percent, and those in the top quartile of responses had Hb F percentages of approximately 21 percent.</p><p>Some of this variability in response to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> appears to be under genetic control, as discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Quantitative trait loci associated with HBG expression'</a>.)</p><p class="headingAnchor" id="H558387868"><span class="h1">INDICATIONS AND EVIDENCE FOR EFFICACY</span></p><p class="headingAnchor" id="H869261479"><span class="h2">Indications and appropriate age to start therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> (hydroxycarbamide, Droxia, Hydrea, Siklos) has been demonstrated to reduce complications and may increase life expectancy in SCD, especially in individuals with the most clinically severe genotypes (Hb SS, sickle beta<sup>0</sup> thalassemia). These benefits are summarized in the table  (<a class="graphic graphic_table graphicRef129652" href="/z/d/graphic/129652.html" rel="external">table 1</a>). </p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> takes weeks to months to be effective and thus is used to prevent complications, not to treat them in the acute setting.</p><p>Our approach to deciding when <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is appropriate in patients with homozygous Hb SS or sickle beta<sup>0</sup> thalassemia is as follows  (<a class="graphic graphic_algorithm graphicRef112513" href="/z/d/graphic/112513.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants 6 to 9 months</strong> – For infants 6 to 9 months with symptomatic disease (severe anemia, dactylitis, acute pain episodes), we consider <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. This is based on indirect evidence from older children and the potential value of preserving high levels of fetal hemoglobin. Limited evidence in this age group demonstrates higher levels of total hemoglobin and lower neutrophil counts at 24 months with early initiation of hydroxyurea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants ≥9 months, children, and adolescents</strong> – For all infants ≥9 months, children, and adolescents, we recommend <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, regardless of disease severity. This is based on secondary endpoints from a randomized trial discussed below and is consistent with 2014 guidelines for SCD management from the National Heart, Lung, and Blood Institute (NHLBI; in the National Institutes of Health [NIH] in the United States).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – For males with Hb SS or sickle beta<sup>0</sup> thalassemia who are taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, we recommend continuing hydroxyurea therapy unless they are attempting to conceive a child in the next three months. </p><p></p><p class="bulletIndent1">For females with Hb SS or sickle beta<sup>0</sup> thalassemia who are taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, this is usually stopped when they become pregnant. Details are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7139.html" rel="external">"Sickle cell disease: Obstetric considerations", section on 'Hydroxyurea'</a>.)</p><p></p><p class="bulletIndent1">For adults not taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, we recommend starting hydroxyurea if they have at least one episode of moderate to severe sickle cell acute pain or acute chest syndrome in the last 12 months, symptomatic anemia, pulmonary hypertension, chronic hypoxemia, or chronic pain impacting their quality of life. We suggest starting hydroxyurea for males with episodes of priapism, adults with chronic kidney disease or proteinuria, or individuals with prior stroke if chronic transfusion therapy is not feasible.</p><p></p><p>Use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in those with other SCD genotypes such as Hb SC disease or sickle beta<sup>+</sup> thalassemia is individualized based on disease severity, which is more variable with these genotypes. We consider hydroxyurea for individuals with clinical manifestations similar to Hb SS or sickle beta<sup>0</sup> thalassemia, and we do not recommend it for those with milder disease. This is based on limited case series that suggest hydroxyurea may be beneficial for patients with Hb SC and significant symptomatology [<a href="#rid39">39,40</a>]; there has been only one small, randomized trial evaluating hydroxyurea for Hb SC.</p><p>This approach is consistent with a 2008 NIH consensus statement on use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in SCD, 2014 guidelines from the NHLBI, an updated systematic review, a 2020 guidelines from the American Society of Hematology (ASH), and practices of other SCD experts [<a href="#rid4">4,34,41-44</a>]. A patient education <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fportal.criticalimpact.com%2Fuser%2F25984%2Ffiles%2FASH_Design_2018-10-09_WEB.pdf&amp;token=hxl%2BStj82nsrBqO2FVOr6iKoHHNkC22XI7840pcmOaUe9NcIQMmQMk3b6wGBQDlRhHaQV3fCJenkqQS5KW%2FwQDN5IWzwq5ifvQoejCYWnjHR1vZPhkjUdyB%2F8yQs%2BhA7&amp;TOPIC_ID=7071" target="_blank">booklet</a> is available from ASH [<a href="#rid45">45</a>].</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> was approved for adults with SCD by the US Food and Drug Administration (FDA) in 1998 and by the European Medicines Agency in 2007 [<a href="#rid16">16</a>]. In 2017, the FDA extended its approval of hydroxyurea to include children with SCD [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may be given concurrently with L-glutamine, <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">voxelotor</a>, or <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">crizanlizumab</a>, and the benefits of the combinations appear to be greater than either agent alone. (See  <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Importance of prevention'</a>.)</p><p class="headingAnchor" id="H2549716608"><span class="h2">Evidence for efficacy</span><span class="headingEndMark"> — </span>Initial evidence for the efficacy of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in SCD came from studies in adults; these were followed soon after by studies in children and then infants [<a href="#rid34">34</a>]. Subsequent prospective observational studies over many years have demonstrated reduced mortality with long-term hydroxyurea. </p><p>Despite the supportive evidence, many individuals with SCD who would benefit from this therapy do not receive it or are treated in a suboptimal manner. Barriers to appropriate therapy should be addressed. (See <a class="local">'Eliminating barriers to appropriate therapy'</a> below.)</p><p class="headingAnchor" id="H4050938936"><span class="h3">Improved survival</span><span class="headingEndMark"> — </span>Evidence for improved survival comes from the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2010 observational study involving 299 individuals with SCD who were originally enrolled in a randomized trial (the Multicenter Study of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> in Sickle Cell Anemia [MSH] trial, described in greater detail below) comparing hydroxyurea with placebo provided &gt;17 years of follow-up [<a href="#rid47">47,48</a>]. Many assigned to placebo had subsequently switched to hydroxyurea after the short-term benefits became apparent. Most of the participants were between 20 and 30 years of age at the time of initial study entry, and only individuals with Hb SS and at least three painful episodes per year were included. The majority of deaths occurred in individuals who were never exposed to hydroxyurea or who had &lt;5 years of exposure. When evaluated according to length of hydroxyurea exposure in five-year increments, death rates per 100 person-years were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Never exposed – 5 deaths per 100 person-years</p><p class="bulletIndent2"><span class="glyph">•</span>&lt;5 years exposure – 6.8 deaths</p><p class="bulletIndent2"><span class="glyph">•</span>5 to 10 years – 4.4 deaths</p><p class="bulletIndent2"><span class="glyph">•</span>10 to 15 years – 1.8 deaths</p><p class="bulletIndent2"><span class="glyph">•</span>≥15 years – 0 deaths</p><p></p><p class="bulletIndent1">Additional benefits documented from the MSH trial are listed below. (See <a class="local">'Reduced complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2010 prospective nonrandomized study involving 131 adults with SCD followed for five to eight years found that mortality was lower in hydroxyurea-treated individuals compared with controls (10 versus 25 percent) [<a href="#rid49">49</a>]. The survival benefit was preserved across multiple SCD genotypes (Hb SS, Hb S beta<sup>0</sup> thalassemia, and Hb S beta<sup>+</sup> thalassemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 retrospective study involving 267 children with SCD (ages 3 to 18 years, all genotypes) treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> for a median of two years found that the hydroxyurea-treated children had lower mortality compared with controls (0.5 versus 5.5 percent [95% CI 0.92-0.99]) [<a href="#rid50">50</a>].</p><p></p><p>General information about survival and prognosis in SCD is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Survival and prognosis'</a>.)</p><p class="headingAnchor" id="H240907234"><span class="h3">Reduced complications</span><span class="headingEndMark"> — </span>Several randomized trials and observational studies have demonstrated reduced SCD complications with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy in different age groups and SCD genotypes  (<a class="graphic graphic_table graphicRef129652" href="/z/d/graphic/129652.html" rel="external">table 1</a>). These effects are most pronounced in individuals with clinically severe disease (frequent pain episodes or acute chest syndrome) and high-risk genotypes (Hb SS or Hb S beta<sup>0</sup> thalassemia). Many of systematic literature summaries and review articles have summarized these results [<a href="#rid42">42,51,52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants</strong> – The 2011 BABY HUG trial randomly assigned 193 infants 9 to 18 months with Hb SS or sickle beta<sup>0</sup> thalassemia irrespective of clinical severity to receive <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (20 mg/kg daily without dose escalation) or placebo for two years [<a href="#rid53">53,54</a>]. The median age at entry was 13.6 months. Primary endpoints included splenic function and glomerular filtration rate (GFR), both of which were chosen because they become abnormal in SCD early in life. Compared with controls, hydroxyurea-treated infants had a trend towards improved splenic function (assessed by cell morphology after qualitative radionucleotide scans were discontinued) and no difference in GFR. However, there were significant reductions in clinical endpoints including pain episodes (hazard ratio [HR] 0.59, 95% CI 0.42-0.83), acute chest syndrome (HR 0.36, 95% CI 0.15-0.87), dactylitis (HR 0.27, 95% CI 0.15-0.50), and constipation (HR 0.33), as well as in need for transfusions (HR 0.55). Therapy was well tolerated with no severe adverse events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – Although there are no randomized trials in children &gt;18 months, observational studies have demonstrated similar benefits as those seen in infants and adults including reduction in painful episodes and hospitalizations [<a href="#rid55">55-57</a>]. In a cohort of 110 children treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, none had an abnormal transcranial Doppler reading (a surrogate marker for stroke risk) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – The 1995 MSH (Multicenter Study of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> in Sickle Cell Anemia) trial randomly assigned 299 adults with Hb SS and at least three painful episodes per year to receive hydroxyurea, titrated to maximum tolerated dose or placebo for approximately two years [<a href="#rid59">59</a>]. The primary outcome was the number of painful episodes, defined as visits to a medical facility lasting &gt;4 hours and resulting in treatment with an opioid, or another vaso-occlusive complication such as acute chest syndrome, priapism, or hepatic sequestration. Compared with controls, the hydroxyurea-treated individuals had a decrease in painful events (median annualized rate, 4.5 versus 2.5 events). The benefit persisted when crises severe enough to cause hospitalization were compared (median annualized rate, 2.4 versus 1.0). There were no differences in the rates of death, stroke, or hepatic sequestration.</p><p></p><p class="bulletIndent1">Extended observation of the original MSH participants suggested a survival benefit after 9 and 17.5 years. (See <a class="local">'Improved survival'</a> above.)</p><p></p><p class="bulletIndent1">A 2010 observational study in which <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> was administered to 131 adults for eight years found similar reductions in painful episodes, acute chest syndrome, hospitalizations, and mortality [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb SC disease</strong> – The CHAMPS trial randomly assigned 44 individuals with Hb SC disease ≥5 years with at least one vaso-occlusive event (painful episode or acute chest syndrome) in the previous year to receive <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> or placebo for 2 to 10 months [<a href="#rid60">60</a>]. There were no differences in clinical events, but the sample size and study duration may have been insufficient to detect a benefit.</p><p></p><p class="bulletIndent1">Retrospective series of children and adults with Hb SC disease who were treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> have documented increases in Hb F levels and decreases in the frequency of acute pain events and hospitalization for pain [<a href="#rid39">39,40</a>].</p><p></p><p>The benefits of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> extend to individuals in resource-limited settings such as sub-Saharan Africa, where SCD is common. Two studies published in 2017 and 2019 demonstrated reduced complications of SCD when hydroxyurea was administered in regions of Africa in which malaria, other infectious diseases, and malnutrition are common [<a href="#rid61">61,62</a>]. A study from 2020 demonstrated the superiority of dose-escalated hydroxyurea over fixed-dose hydroxyurea in children in sub-Saharan Africa (median dose in the dose-escalated group, 29.5±3.6 mg/kg per day, versus 19.2±1.8 mg/kg per day in the fixed dose group) [<a href="#rid63">63</a>]. Children treated with dose-escalated hydroxyurea had fewer SCD complications (incidence rate ratio [IRR] 0.43, 95% CI 0.34-0.56). Hydroxyurea therapy was also associated with lower malaria incidence [<a href="#rid64">64</a>]. Use of hydroxyurea in sub-Saharan Africa, including indications, dosing, and monitoring, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Hydroxyurea'</a>.) </p><p>Stroke prevention trials have generally shown that chronic transfusions are effective for primary and secondary prevention, although there is evidence of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> noninferiority in a subset of individuals at high risk for a first stroke who have received chronic transfusions for ≥2 years. There is also limited evidence that hydroxyurea alone can prevent progression from conditional to abnormal TCD screening results and may reduce stroke risk in patients with abnormal TCD results who do not have access to transfusion therapy. (See  <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Hydroxyurea in primary stroke prevention'</a>.)</p><p>Adverse effects are discussed below. (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H342750584"><span class="h3">Other benefits</span><span class="headingEndMark"> — </span>Other potential benefits of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> include improved quality of life and daily functioning. These in turn may translate to better school attendance and fewer days lost from work. A retrospective cohort study compared quality of life in 191 children with SCD. Those treated with hydroxyurea reported better overall health-related quality of life (HRQL) and better physical HRQL than children who did not receive hydroxyurea [<a href="#rid65">65</a>].</p><p>Cost savings due to reduced clinical encounters and hospitalizations may also be seen [<a href="#rid66">66,67</a>]. In the BABY HUG trial, which randomly assigned young children to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> versus placebo, hydroxyurea was associated with a 21 percent annual cost savings due to reduced hospitalizations [<a href="#rid67">67</a>]. A similar cost reduction was not demonstrated in the Multicenter Study of Hydroxyurea (MSH) [<a href="#rid47">47,48</a>].</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may also reduce neurocognitive deficits. In a retrospective cohort of 152 patients with Hb SS or Hb S beta<sup>0</sup> thalassemia, earlier initiation of hydroxyurea was associated with higher scores on neurocognitive measures [<a href="#rid68">68</a>]. This benefit was preserved even after adjustment for confounders including social vulnerability, sex, and duration of treatment. Across a variety of genotypes, patients treated with hydroxyurea demonstrated a six-point elevation in intelligence quotient (IQ) compared with untreated patients.</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may also reduce the risk and/or severity of malaria. (See <a class="local">'Reduced complications'</a> above and  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Malaria'</a>.)</p><p class="headingAnchor" id="H1623646123"><span class="h1">ELIMINATING BARRIERS TO APPROPRIATE THERAPY</span><span class="headingEndMark"> — </span>Despite the clear clinical benefits of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (see <a class="local">'Evidence for efficacy'</a> above), many individuals are treated with hydroxyurea in a suboptimal manner or do not receive this therapy at all [<a href="#rid4">4,34,41,69-76</a>]. This lack of hydroxyurea use has been demonstrated in large reviews such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – A database review identified 7963 children with SCD in six states in the United States during the period from 2005 to 2012, representing 22,424 person-years [<a href="#rid73">73</a>]. Among all person-years, 78 percent had 0 days of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in a year; 3 percent had 1 to 30 days, and 20 percent had &gt;30 days. Of those who received hydroxyurea, the average number of days' supply in a year was 189. Factors predictive of receiving hydroxyurea included younger age of the child and more frequent outpatient visits. The odds of receiving hydroxyurea did not increase over the course of the study, and in fact, it appears to have decreased in the final years. </p><p></p><p class="bulletIndent1">Subsequent studies, each including &gt;5000 children with SCD enrolled in Medicaid (government-sponsored health care in the United States) reported:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An increase in <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> use from 14 percent in 2009 to 28 percent in 2015 [<a href="#rid74">74</a>]. </p><p class="bulletIndent2"><span class="glyph">•</span>An increase from 7 percent in 2004 to 22 percent in 2019 (data limited to the state of Georgia) [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – A database review identified 2086 adults with SCD based on insurance codes identified 677 (approximately one-third) who had at least three pain-related hospitalizations or emergency department visits within a one-year period [<a href="#rid75">75</a>]. However, only 86 of these individuals with frequent painful episodes (15 percent) filled a prescription for <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> within three months of the third encounter; this percentage increased to 23 percent at one year. </p><p></p><p>These data suggest that significant barriers to appropriate therapy persist even following publication of the 2014 practice guideline from the National Heart, Lung, and Blood Institute (NHLBI), which recommended <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> for all infants, children, and adolescents with SCD regardless of symptoms, as well as for adults with three or more vaso-occlusive episodes in a year [<a href="#rid43">43</a>]. Evidence-based strategies are required to address best practices to improve adherence to hydroxyurea in children and adults with SCD.</p><p>Several studies have defined specific and extensive barriers to appropriate administration of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> that include patient-, parent/family/caregiver-, provider-, and system-level obstacles. Examples include [<a href="#rid77">77,78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hesitancy among members of the health care team about the safety and efficacy of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a></p><p class="bulletIndent1"><span class="glyph">●</span>Patient concerns about carcinogenicity, teratogenicity, and other side effects</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty in complying with daily dosing, obtaining refills in a timely fashion, and adhering to frequent clinical and laboratory monitoring</p><p class="bulletIndent1"><span class="glyph">●</span>For children, limited access to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> solution, which can be prepared only by specialized compounding pharmacies</p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, inadequate health insurance coverage among those who live in poverty, especially with the high cost of the <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> formulation approved for children (Siklos) </p><p></p><p>To ensure adherence and maximal benefit from <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, clinicians can clearly present the risks, benefits, and practical aspects of administration. </p><p class="headingAnchor" id="H364722276"><span class="h1">BASELINE TESTING</span><span class="headingEndMark"> — </span>We obtain the following studies before starting <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with red blood cell indices, white blood cell differential, platelet count</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin F (Hb F) percentage (quantitative measure)</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test for females of childbearing potential</p><p></p><p>The baseline mean corpuscular volume (MCV) should be noted because <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> causes macrocytosis and might mask iron, B12, or folate deficiency. If the baseline MCV is high, we check vitamin B12 and folate levels if the history is suggestive of vitamin deficiency associated with increased MCV and thyroid studies if a family history or symptoms are suggestive of thyroid disease. (See  <a class="medical medical_review" href="/z/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Causes of macrocytosis/macrocytic anemia'</a>.)</p><p>If the baseline MCV is low, we take a dietary history for possible iron deficiency and consider whether the patient may have alpha thalassemia trait, an established risk factor for low MCV values. Approximately 40 percent of unselected children with Hb SS or sickle beta<sup>0</sup> thalassemia will have single alpha globin gene deletion. Thus, consistently low MCV levels are most likely related to alpha globin gene deletion. Those with acquired microcytosis should be evaluated for iron deficiency (see  <a class="medical medical_review" href="/z/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'Causes of microcytosis'</a>). Individuals with renal insufficiency are treated with a lower initial dose of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. (See <a class="local">'Dosing in chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H3109840581"><span class="h1">ADMINISTRATION AND DOSING</span></p><p class="headingAnchor" id="H2497605616"><span class="h2">Initial dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is initiated at a low dose and gradually increased to a dose that does not cause severe hematologic toxicity. (See <a class="local">'Monitoring and dose titration'</a> below.)</p><p>The dose is administered as a single once-daily dose, although it can be given in divided doses if this is preferable to the patient. To improve adherence, a single <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> dose per day is recommended.</p><p>Gastrointestinal upset may improve if the dose is given at bedtime. (See <a class="local">'GI side effects'</a> below.) </p><p>A lower initial dose is used for individuals with impaired kidney function. (See <a class="local">'Dosing in chronic kidney disease'</a> below.)</p><p>Concomitant use of L-glutamine or <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">crizanlizumab</a> does not affect <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> dosing. Concomitant use of <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">voxelotor</a> may affect hydroxyurea dosing since voxelotor lowers the ARC, one of the criteria for determining MTD.</p><p class="headingAnchor" id="H2547708256"><span class="h3">Infants and young children</span><span class="headingEndMark"> — </span>For infants younger than one year of age treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> who have good kidney function (creatinine clearance &gt;60 mL/minute), we use an initial dose of 20 mg/kg per day. This starting dose was well tolerated in the BABY HUG and NOHARM trials [<a href="#rid53">53,61,79</a>].</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is not commercially available as a liquid; compounding pharmacy support is required to prepare an oral solution from the commercially available capsules. Such oral solutions (typical concentration, 100 mg/mL) have been shown to be chemically stable at room temperature for up to six months [<a href="#rid80">80</a>]. </p><p>The dose can be rounded off to the nearest 2.5 mg/kg (eg, give 200 mg instead of 180 mg for a 9 kg infant, or 400 mg instead of 440 mg for a 22 kg child).</p><p>If cost and lack of access to a reliable compounding pharmacy for the oral solution are a barrier, the following may be useful:</p><p class="bulletIndent1"><span class="glyph">●</span>One formulation (brand name, Siklos) is available as 100 mg and scored 1000 mg tablets that can be dissolved in water [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose can be rounded to the nearest available capsule size and the capsules can be opened and mixed into a small quantity of food. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Different doses can be used on different days of the week. For example, if the desired <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> dose is 1250 mg daily, the child can receive 1000 mg on Monday, Tuesday, Wednesday, and Thursday, and 1500 mg on Friday, Saturday, and Sunday. This averages to a weekly dose of 1250 mg/day.</p><p></p><p>Monitoring and dose titration is described below. (See <a class="local">'Monitoring and dose titration'</a> below.)</p><p class="headingAnchor" id="H3934995084"><span class="h3">Older children, adolescents, and adults</span><span class="headingEndMark"> — </span>Individuals who are able to take <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in pill form are given a dose in increments rounded to the nearest capsule size. Capsules are available in 200 mg, 300 mg, 400 mg, and 500 mg doses.</p><p class="bulletIndent1"><span class="glyph">●</span>The recommended initial oral dose of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> for children with a creatinine clearance &gt;60 mL/min is 20 mg/kg per day, rounded to the nearest 2.5 mg/kg per day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults may be started on 15 to 20 mg/kg per day with lower doses for older adults and those with normal to mildly reduced glomerular filtration rates. </p><p></p><p>Monitoring and dose titration is described below. (See <a class="local">'Monitoring and dose titration'</a> below.)</p><p class="headingAnchor" id="H1873038639"><span class="h3">Dosing in chronic kidney disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is excreted by the kidney, and individuals with end-stage kidney disease or creatinine clearance &lt;60 mL/minute may have higher exposure for a given dose.</p><p>In these individuals, we typically start at half the starting dose that would be used for normal kidney function (7.5 mg/kg daily rather than 15 mg/kg daily). Smaller increments of dose titration may also be used in these individuals.</p><p>It is important to continue to monitor kidney function during dose titration. (See <a class="local">'Monitoring and dose titration'</a> below.)</p><p class="headingAnchor" id="H3152316409"><span class="h2">Monitoring and dose titration</span><span class="headingEndMark"> — </span>Reduction in vaso-occlusive events is the most patient-important clinical endpoint. Bone marrow suppression is the major dose-limiting toxicity. </p><p>Although clinical benefit is the goal, we use hematologic parameters as a surrogate for clinical benefit and an endpoint for dose titration, referred to as the maximum tolerated dose (MTD)  (<a class="graphic graphic_table graphicRef107002" href="/z/d/graphic/107002.html" rel="external">table 2</a>). </p><p>Monitoring is more frequent while the dose is being adjusted and continues at less frequent intervals once the individual is on a stable dose. In resource-limited settings where frequent complete blood counts (CBCs) are not an option, less intensive dosing with less frequent monitoring may be feasible and may reduce vaso-occlusive complications, including stroke. (See  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Hydroxyurea'</a>.)</p><p>There is some nuance to determining the ideal set of parameters to monitor that balances ease of use and cost with the added benefit of including more parameters. Some experts advocate hemoglobin/hematocrit and absolute reticulocyte count (ARC), as long as the additional monitoring is not a disincentive to prescribing <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>.</p><p>A 2019 pharmacokinetic model for <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in children indicated that patients could reach maximum tolerated dose (MTD) faster using pharmacokinetic-guided dosing than with the standard increment of 5 mg/kg dose every eight weeks [<a href="#rid82">82</a>]. A separate study determined that a dose-prediction equation incorporating baseline serum creatinine, body mass index, and ARC was superior to standard dose escalation in reaching MTD more rapidly [<a href="#rid83">83</a>]. MTD was higher in the dose-prediction arm, suggesting that standard dose escalation results in falsely low MTD in very young children. Although MTD was reached more rapidly in both studies, there was no evidence of decreased morbidity from SCD. </p><p>Detailed criteria for determining eligibility for dose escalation, MTD, and toxicity are presented in the table  (<a class="graphic graphic_table graphicRef107002" href="/z/d/graphic/107002.html" rel="external">table 2</a>). General principles include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight-based initial dose</strong> – The initial dose is calculated based on weight, as indicated above. (See <a class="local">'Initial dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increasing the dose</strong> – The dose is increased approximately every eight weeks (range, 6 to 12 weeks) by 5 mg/kg daily, to a maximum dose of 35 mg/kg daily or 2500 mg daily, or until one or more of the MTD parameters are reached. The complete blood count (CBC) and reticulocyte count should be obtained every four weeks while the dose is being increased as the hematologic response may evolve over this period.</p><p></p><p class="bulletIndent1">Parameters to determine MTD include any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An absolute neutrophil count (ANC) (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>) of 1500 to 3000/microL (infants with lower baseline ANC may tolerate an on-therapy ANC as low as 1000/microL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARC of 80,000 to 100,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A platelet count of 80,000 to 150,000/microL</p><p></p><p class="bulletIndent1">In practice, the most common parameter determining MTD is the ANC, but in some patients the target ARC will be reached before the target ANC. Reduction of the platelet count is rarely the criterion for determining MTD except in patients with splenomegaly.</p><p></p><p class="bulletIndent1">Reticulocytopenia and worsening anemia occurs more frequently in patients with chronic kidney disease, iron deficiency, viral bone marrow suppression, or delayed hemolytic transfusion reactions [<a href="#rid84">84-87</a>]. A low ARC with anemia may be a more common reason to hold <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in adults who are hospitalized or have significant comorbidities; it may be less common in children.</p><p></p><p class="bulletIndent1">In patients with a strong hemoglobin response (hemoglobin &gt;9 g/dL), ARC &lt;80,000/microL is acceptable as long as the hemoglobin remains stable over several months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Holding the dose for significant cytopenias</strong> – If significant cytopenias develop (ANC &lt;1000/microL, platelet count &lt;80,000/microL), the dose is temporarily held and the CBC rechecked once per week until the value exceeds that listed above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If recovery occurs within a week, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is then restarted at the same dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If myelosuppression was prolonged or recurs, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is restarted at a lower previously tolerated dose (2.5 to 5 mg/kg daily less than the dose that caused hematologic toxicity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb F percentage</strong> – Routine monitoring of Hb F percentage is not necessary as it is not used to titrate the dose, although it may be checked periodically (eg, annually) to evaluate efficacy. </p><p></p><p class="bulletIndent1">Most <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> responses are associated with at least a twofold increase in Hb F percentage over baseline, often much greater. Hb F &gt;20 percent of total hemoglobin is ideal; there is no upper limit [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1">Greater increases percent Hb F or total hemoglobin (&gt;1 g/dL) generally correlate with greater efficacy. Some studies have suggested maximal Hb F response as a surrogate for adherence, but not all individuals who adhere to therapy have a major increase in Hb F; judgement must be used [<a href="#rid88">88</a>]. (See <a class="local">'Increased Hb F production'</a> above and <a class="local">'Lack of hematologic response'</a> below.)<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy test</strong> – In females of childbearing potential, a pregnancy test should be done if menses are delayed &gt;2 weeks. Discussion about the teratogenic impact of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> and contraception options should be discussed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring on stable dosing</strong> – Once the MTD is reached, monitoring is continued at less-frequent intervals. Ongoing monitoring is needed because dose effects and kidney function can change over time. </p><p></p><p class="bulletIndent1">The CBC with platelet count and reticulocyte count can be measured once every three months. Liver and kidney function are evaluated as needed for ongoing monitoring of SCD (at least every 12 months, more frequently if there is known or suspected organ dysfunction). Additional monitoring may be needed if there is an intercurrent illness that might affect kidney or bone marrow function.</p><p></p><p class="headingAnchor" id="H4031281268"><span class="h2">Can therapy be discontinued?</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> therapy should be continued for as long as it is tolerated and effective. </p><p>Exceptions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent cytopenias despite dose reductions, which can be a sign of reduced bone marrow capacity.</p><p></p><p class="bulletIndent1">Other causes of cytopenias (kidney or liver disease, nutritional deficiencies, hypothyroidism) should be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening kidney function, which may increase the risk of excessive exposure due to delayed clearance of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, as well as of decreased erythropoiesis due to decreased erythropoietin production. </p><p></p><p class="bulletIndent1">This can usually be managed by reducing the dose and sometimes by adding an erythropoiesis stimulating agent (ESA) if the primary toxicity is reticulocytopenia. (See <a class="local">'Myelosuppression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe cutaneous toxicity, pancreatitis, or other adverse effects that interfere with quality of life. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For males, three months prior to attempting conception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For females who become pregnant. (See <a class="local">'Pregnancy and breastfeeding'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who have a complication necessitating chronic (regular) transfusion therapy while taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> may discontinue hydroxyurea if the complication occurred despite hydroxyurea therapy. (See <a class="local">'Hospitalization'</a> below.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Adverse effects of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in individuals with SCD have been assessed in several studies, as summarized in the table  (<a class="graphic graphic_table graphicRef63410" href="/z/d/graphic/63410.html" rel="external">table 3</a>). </p><p>Evidence from over 30 years of use in individuals with SCD has demonstrated a lack of clinically significant adverse effects on growth or development with long-term use. This includes very young children enrolled in the BABY HUG trial (ages 9 to 18 months), who had no reduction in growth or other anthropomorphic measures during two years of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy [<a href="#rid89">89</a>].</p><p>The BABY HUG trial is one of the few trials that compared fixed moderate dose <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> at 20 mg/kg/day with placebo in children with sickle cell anemia (SCA) [<a href="#rid53">53</a>]. Infants treated with hydroxyurea did not have significant differences from those treated with placebo in rates of severe neutropenia (absolute neutrophil count [ANC] &lt;500/microL), thrombocytopenia (platelet count &lt;80,000/microL), anemia (hemoglobin &lt;7 g/dL), reticulocytopenia (absolute reticulocyte count [ARC] &lt;80,000/microL), or abnormal liver function tests (alanine aminotransferase [ALT] &gt;150 units/L or bilirubin &gt;10 mg/dL).</p><p class="headingAnchor" id="H2466845915"><span class="h2">Impact on vaccination</span><span class="headingEndMark"> — </span>The package insert for <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> states that live virus vaccines should be avoided. We have not encountered any problems related to live vaccines, and we provide all routine vaccinations to individuals receiving hydroxyurea, including live virus vaccines. The benefits of reducing infections in this population of functionally asplenic individuals is likely to outweigh any risks associated with live vaccines. </p><p>The BABY HUG trial measured immunological effects of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> including T-cell subsets, naïve and memory T-cells and antibody response to inactivated and live vaccines [<a href="#rid90">90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> treatment resulted in lower total lymphocytes, CD4-positive T-cells, and memory T-cells; however, counts remained within the normal range for healthy children. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibody responses to vaccines for pneumococcus, mumps, and rubella were unchanged, but there was a delay of 14 days in developing protective levels of measles antibody. </p><p></p><p class="headingAnchor" id="H3290537625"><span class="h2">Myelosuppression</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is relatively nontoxic, with myelosuppression as the major dose-limiting toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span>For most individuals, myelosuppression is predictable, dose-dependent, and reversible [<a href="#rid39">39,40,47,48</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myelosuppression is used to adjust <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> dosing and can be easily controlled as long as there is regular hematologic monitoring and dose reduction for severe neutropenia, anemia, or thrombocytopenia. (See <a class="local">'Monitoring and dose titration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some individuals have severe myelosuppression such that they are unable to tolerate even low doses of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. (See <a class="local">'Severe myelosuppression'</a> below.)</p><p></p><p class="headingAnchor" id="H3620003872"><span class="h2">Falsely elevated serum creatinine and other laboratory tests</span><span class="headingEndMark"> — </span>A point-of-care device for measuring serum creatinine (the i-STAT system) used for routine testing in some clinical laboratories can give a falsely elevated creatinine measurement in patients receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid91">91</a>].</p><p>Individuals receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> who have a high serum creatinine should be retested using a different method to distinguish this artifact from true kidney disease. (See  <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Role of hydroxyurea and transfusions'</a>.)</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> has also been reported to cause falsely elevated results for urea, uric acid, and lactic acid, due to analytical interference with the enzymes used to determine these values.</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> may falsely elevate glucose readings on certain continuous glucose monitoring (CGM) systems, with the potential for excessive dosing of insulin and resulting hypoglycemia [<a href="#rid92">92</a>]. The clinician treating diabetes should be informed of this concern. (See  <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'CGM systems'</a>.)</p><p class="headingAnchor" id="H3726393395"><span class="h2">GI side effects</span><span class="headingEndMark"> — </span>Some individuals receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> may have gastrointestinal (GI) toxicity with nausea or anorexia. </p><p>In the HUG-KIDS study, the two children with GI upset attributed to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> had improvement in symptoms when the dose was given at bedtime.</p><p class="headingAnchor" id="H254947702"><span class="h2">Dermatologic</span><span class="headingEndMark"> — </span>Skin and nail changes and leg ulcers have been described, although it is not clear whether <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> was responsible [<a href="#rid42">42</a>].</p><p>Individuals with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> overdose have developed mucocutaneous toxicity, with erythema and soreness on the palms and soles of the hands and feet; scaling, generalized hyperpigmentation; and/or stomatitis. In such cases the dose should be stopped and supportive treatments used.</p><p class="headingAnchor" id="H2939245104"><span class="h2">Pregnancy outcomes</span><span class="headingEndMark"> — </span>Data on adverse pregnancy outcomes are extremely limited, and decisions regarding discontinuation (whether to discontinue, timing of stopping and restarting) must be individualized and take into account the direct risks to the fetus and mother and the indirect risks due to increased vaso-occlusive episodes and availability of other disease-modifying approaches such as chronic transfusion therapy while not taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. These subjects are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7139.html" rel="external">"Sickle cell disease: Obstetric considerations", section on 'Hydroxyurea'</a>.)</p><p>Possible effects on fertility are discussed below. (See <a class="local">'Fertility'</a> below.)</p><p class="headingAnchor" id="H2079317780"><span class="h2">Fertility</span><span class="headingEndMark"> — </span>One of the consistently noted barriers to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy has been a concern about possible effects on fertility, especially since SCD may already confer a reduction in sexual functioning, sperm counts, or other reproductive factors [<a href="#rid93">93,94</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Males</strong> – There has been concern based on data from animal models that suggest a further reduction in spermatogenesis with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. However, preliminary data from two pilot studies provide some reassurance that fertility is unlikely to be permanently impaired by the drug. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, sperm parameters were compared in 15 adolescents and young adults with SCD who were treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> during childhood (median duration, 4 years) and 23 controls who had not received hydroxyurea [<a href="#rid95">95</a>]. Most had more than one sample analyzed. There were abnormalities of sperm number and quality, but sperm parameters were not adversely affected in the individuals treated with hydroxyurea. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study, 30 boys with SCD who were undergoing hematopoietic stem cell transplant had harvesting of testicular tissue for fertility preservation; 17 had been treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (for a median of 36 months) and 13 had not, allowing a comparison between groups [<a href="#rid96">96</a>]. On histological examination of resected testicular tissue, spermatogonial tissue was similar between groups. However, compared with controls without SCD, all of the children with SCD had a reduced spermatogonial stem cell pool, indicating that SCD contributes to spermatogonial depletion.</p><p></p><p class="bulletIndent1">It is possible that earlier cohort studies that observed reduced sperm counts and low sperm quality may have reflected changes due to SCD rather than <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, although they do not eliminate a possible role for hydroxyurea in reduced male fertility [<a href="#rid97">97,98</a>]. If an effect on fertility exists, it is not known whether the effect is reversible with cessation of hydroxyurea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Females</strong> – There are few data on the impact of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy on female fertility in SCD [<a href="#rid94">94</a>]. </p><p></p><p class="bulletIndent1">A study from 2020 found an association between <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> and decreased ovarian reserve, using anti-müllerian hormone (AMH) as a marker [<a href="#rid99">99</a>]. In a multivariable analysis, hydroxyurea use was associated with decreased AMH levels. Further research in this area is needed so that individuals can be accurately counseled about this possible risk and be offered measures for fertility preservation when appropriate. (See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Anti-müllerian hormone'</a>.)</p><p></p><p class="headingAnchor" id="H1030914194"><span class="h2">No evidence for carcinogenicity</span><span class="headingEndMark"> — </span>A theoretical concern with long-term <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is whether the drug is a carcinogen in individuals with SCD. This concern is mostly based on reports of increased incidence of malignancy in individuals receiving hydroxyurea for myeloproliferative neoplasms (MPNs), for whom the baseline risk of hematologic malignancy is increased. Even for these MPNs, it is not clear whether hydroxyurea is a mild leukemogen or whether it merely unmasks the risk of leukemia by allowing patients to live longer.</p><p>There is no evidence from the published literature or our clinical experience that suggests individuals with SCD receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> have an increased risk of malignancy compared with individuals with SCD who are not receiving hydroxyurea. </p><p class="bulletIndent1"><span class="glyph">●</span>Reports from 2003 and 2010 described long-term outcomes in 233 adults who participated in the Multicenter Study of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> in Sickle Cell Anemia (MSH) trial, which evaluated the role of hydroxyurea in reducing painful episodes [<a href="#rid47">47,48</a>]. Nine years after the trial started, three patients had developed a malignancy, including one each of breast, cervix, and uterus cancer. At least one of the three patients had a preexisting condition predisposing to increased cancer risk. There were no additional cancers described after an additional 17.5 years of follow-up, with an overall rate of malignancy of 0.1 per 100 patient-years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2004 report described outcomes in 122 children treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> for up to eight years [<a href="#rid100">100</a>]. There were no malignancies or myelodysplasia, and in vitro testing for increased DNA mutations using VDJ rearrangements in 26 of the children showed no evidence of mutagenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2011 report tested in vitro parameters of chromosome stability in 50 children with SCD who had received <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> for up to 12 years compared with 28 children who had not received hydroxyurea [<a href="#rid101">101</a>]. Compared with controls, the children who had received hydroxyurea had <strong>less </strong>chromosome damage and similar chromosome repair.</p><p></p><p>Additional long-term studies are needed, as people with SCD have an increased risk of hematologic malignancies without exposure to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid102">102</a>]. </p><p>While it is possible that these studies failed to detect a very small increase in carcinogenicity, this risk, if present, must be weighed against the clinically significant benefits of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in reducing complications and prolonging survival. (See <a class="local">'Evidence for efficacy'</a> above.)</p><p class="headingAnchor" id="H2342958301"><span class="h1">SPECIAL SCENARIOS</span></p><p class="headingAnchor" id="H817846651"><span class="h2">Lack of hematologic response</span><span class="headingEndMark"> — </span>Lack of hematologic response (hemoglobin F [Hb F] increasing by less than twofold, mean corpuscular volume [MCV] ≤100 fL, or MCV increased by &lt;10 fL) is sometimes seen and is usually attributed to reduced medication adherence. </p><p>Often, medication nonadherence is the reason for lack of a hematologic response; however, lack of response should not automatically be used as a surrogate for nonadherence, because a significant proportion of individuals who take <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> as directed do not have a hematologic response. </p><p>When efficacy is carefully tracked and compliance is assumed to be 100 percent, it appears that approximately 5 to 10 percent of children and 25 to 30 percent of adults have true lack of efficacy from <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid9">9</a>]. The reason is not completely understood but may be due to factors that control Hb F production. (See <a class="local">'Mechanism of action'</a> above.)</p><p>For an individual who does not have the expected response, the following is appropriate:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Review administration</strong> – Proper daily use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> should be reviewed and barriers to proper use addressed. (See <a class="local">'Eliminating barriers to appropriate therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimize adherence</strong> – Adherence should be reviewed and optimized as best as possible before significant dose escalation to reduce the risk of excessive myelosuppression at higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allow six months of therapy</strong> – If the individual has only been taking the medication for a short time, we continue therapy for six months after the maximum tolerated dose (MTD) has been reached. (See <a class="local">'Monitoring and dose titration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focus on clinical benefit</strong> – If the patient has clinical benefit from treatment despite lack of the expected hematologic changes, we continue the medication as long as there are no apparent adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consider adding an ESA</strong> – An erythropoiesis stimulating agent (ESA) can be added to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, typically at doses similar to those used for cancer or inflammatory causes of anemia. This approach was suggested in the American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease [<a href="#rid103">103</a>]. Individuals with kidney disease and older individuals have increased endogenous erythropoietin but not to the markedly elevated levels typically seen in young people with SCD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Address nutrient deficiencies</strong> – Iron, vitamin B12, or folate deficiency may limit response to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. If the patient's clinical or laboratory picture suggests these possibilities, assess and supplement as needed. Ferritin may be in the normal range or even elevated in people with SCD with absent bone marrow stores, due to chronic inflammation [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stop for true lack of benefit </strong>– If the patient is taking the drug as directed and not experiencing any clinical benefit (no reduction in pain episodes or other vaso-occlusive complications) and/or is not having the expected hematologic changes, we may discontinue the medication, as the risks of continuing therapy, albeit small, may no longer be justified. </p><p></p><p class="bulletIndent1">For these patients, other options include other disease-modifying therapies, chronic transfusions, investigative agents, and hematopoietic cell transplantation. These approaches are not mutually exclusive. The choice among them is individualized according to the needs of the individual. The risks and benefits of these therapies are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a> and  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1610161953"><span class="h2">Severe myelosuppression</span><span class="headingEndMark"> — </span>Some individuals treated with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> may have more severe myelosuppression than expected. Typically, the drug is held and restarted at a lower dose, and a maximum tolerated dose can eventually be determined. (See <a class="local">'Monitoring and dose titration'</a> above.)</p><p>Rarely, an individual may be unable to tolerate <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> even at reduced doses (eg, with severe kidney dysfunction). For these patients, options for treatment include chronic transfusion therapy, investigational agents, hematopoietic cell transplantation, and supportive/symptomatic care. The choice among these is individualized. Risks and benefits are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a> and  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H1087048061"><span class="h2">Transition from chronic transfusions to hydroxyurea</span><span class="headingEndMark"> — </span>Selected individuals can be transitioned from chronic transfusions to <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy, as shown in the table  (<a class="graphic graphic_table graphicRef107002" href="/z/d/graphic/107002.html" rel="external">table 2</a>). This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Chronic transfusion followed by transition to hydroxyurea'</a>.)</p><p class="headingAnchor" id="H4245273999"><span class="h2">Pregnancy and breastfeeding</span><span class="headingEndMark"> — </span>Decisions about <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> during attempted conception, pregnancy, and breastfeeding are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7139.html" rel="external">"Sickle cell disease: Obstetric considerations", section on 'Hydroxyurea'</a>.)</p><p class="headingAnchor" id="H2836945892"><span class="h2">Hospitalization</span><span class="headingEndMark"> — </span>Patients receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> should continue the drug during an acute hospitalization unless there is significant myelosuppression or severe acute kidney injury, both of which would warrant discontinuation and possibly restarting at a lower dose. (See <a class="local">'Initial dosing'</a> above.)</p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> generally can be continued during hospitalization for a febrile illness or an uncomplicated infection. It is prudent to temporarily hold hydroxyurea during severe infectious illnesses with worsening cytopenias or worsening clinical status in order to avoid severe myelosuppression. </p><p>We do not hold <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy before surgery, because the major concern postoperatively is acute chest syndrome (ACS), and hydroxyurea decreases this risk. ACS is potentially life-threatening, and its risk reduction outweighs a risk of poor wound healing from myelosuppression. </p><p><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is also continued for individuals who are admitted for complications that require transfusions, as the effect of transfusions is likely to be transient. For those who are transitioned to chronic (regular) transfusion therapy, hydroxyurea may be discontinued, since the complication that necessitated transfusion occurred despite hydroxyurea. Restarting the hydroxyurea at a future time may be appropriate; this decision is individualized.</p><p>For those who are unable to take anything by mouth, <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> must be held, as there is no parenteral formulation. The medication should be restarted as soon as reasonably possible, using the nasogastric route when necessary.</p><p>If a patient with SCD who is not receiving <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is hospitalized and a decision is made to start the medication, this is typically done on an outpatient basis to allow for full discussion of the risks and benefits and establishment of a mutually agreed upon surveillance schedule. </p><p class="headingAnchor" id="H334495207"><span class="h2">Resource-limited settings</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Hydroxyurea'</a>.)</p><p class="headingAnchor" id="H730353735"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H11335462"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16730.html" rel="external">"Patient education: Sickle cell disease (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/88642.html" rel="external">"Patient education: When your child has sickle cell disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1780217722"><span class="h1">PATIENT PERSPECTIVE TOPIC</span></p><p>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> reduces vaso-occlusive events such as pain and acute chest syndrome (ACS) in people with sickle cell disease (SCD). The most important mechanism is an increase in fetal hemoglobin (Hb F), which reduces sickle hemoglobin (Hb S) polymerization, sickling, and vaso-occlusion. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is effective in improving survival and reducing complications of SCD  (<a class="graphic graphic_table graphicRef129652" href="/z/d/graphic/129652.html" rel="external">table 1</a>). Our approach to deciding whether to use hydroxyurea is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef112513" href="/z/d/graphic/112513.html" rel="external">algorithm 1</a>). (See <a class="local">'Indications and evidence for efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants ≥9 months, children, and adolescents with Hb SS or sickle beta<sup>0</sup> thalassemia, we recommend <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). A randomized trial and several observational studies demonstrated reductions in vaso-occlusive complications (dactylitis, painful episodes, acute chest syndrome). Hydroxyurea may be considered in selected infants between six and nine months. (See <a class="local">'Infants and young children'</a> above and <a class="local">'Older children, adolescents, and adults'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adults with homozygous Hb SS and sickle beta<sup>0</sup> thalassemia, we continue (or offer) <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> unless trying to conceive in the next three months (males) or pregnant (females). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals with Hb SC disease or sickle beta<sup>+</sup> thalassemia, use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> is individualized based on disease severity. We consider hydroxyurea for those with clinical manifestations similar to Hb SS or sickle beta<sup>0</sup> thalassemia and do not recommend it for those with milder disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> in sub-Saharan Africa is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Hydroxyurea'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline testing</strong> – Testing prior to initiating <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> includes complete blood count (CBC) with differential, platelet count, reticulocyte count, Hb F percentage, tests of kidney and liver function, and pregnancy test for females of childbearing potential. (See <a class="local">'Baseline testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – We generally start infants and children at 20 mg/kg daily and adults at 15 to 20 mg/kg daily; the daily dose may be rounded to the nearest 2.5 mg/kg. For creatinine clearance &lt;60 mL/minute, reduce the dose by one-half. The dose is typically titrated by 5 mg/kg/day every eight weeks to maximum tolerated dose (MTD) using hematologic parameters  (<a class="graphic graphic_table graphicRef107002" href="/z/d/graphic/107002.html" rel="external">table 2</a>). Compounding support is needed to create a liquid formulation. Treatment is continued indefinitely if effective. (See <a class="local">'Administration and dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> is relatively nontoxic. Myelosuppression is the predictable, dose-limiting toxicity  (<a class="graphic graphic_table graphicRef63410" href="/z/d/graphic/63410.html" rel="external">table 3</a>). Skin, hair, and nail changes and gastrointestinal upset may occur. Some serum creatinine assays and continuous glucose monitor readings may be altered. Reduced sperm number and quality may occur without hydroxyurea, and preliminary data suggest hydroxyurea does not worsen these parameters. Concerns have been raised about possible carcinogenesis; further studies are needed. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of response</strong> – (See <a class="local">'Lack of hematologic response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives to </strong><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> – Separate topics discuss:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SCD management</strong> – (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical therapies</strong> – (See  <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic transfusions</strong> – (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematopoietic stem cell transplant and gene therapy</strong> – (See  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1100215818"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges extensive contributions of Donald H Mahoney, Jr, MD, to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf 2015; 14:1749.</a></li><li><a class="nounderline abstract_t">Singh A, Xu YJ. The Cell Killing Mechanisms of Hydroxyurea. Genes (Basel) 2016; 7.</a></li><li><a class="nounderline abstract_t">Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017.</a></li><li><a class="nounderline abstract_t">Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358:1362.</a></li><li><a class="nounderline abstract_t">Goldberg MA, Brugnara C, Dover GJ, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990; 323:366.</a></li><li><a class="nounderline abstract_t">Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006; 108:1073.</a></li><li><a class="nounderline abstract_t">Setty BN, Kulkarni S, Dampier CD, Stuart MJ. Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood 2001; 97:2568.</a></li><li><a class="nounderline abstract_t">Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989; 32:104.</a></li><li><a class="nounderline abstract_t">Rodgers GP, Dover GJ, Noguchi CT, et al. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990; 322:1037.</a></li><li><a class="nounderline abstract_t">Estepp JH, Smeltzer MP, Kang G, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol 2017; 92:1333.</a></li><li><a class="nounderline abstract_t">Perrine RP, Pembrey ME, John P, et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med 1978; 88:1.</a></li><li><a class="nounderline abstract_t">Wood WG, Pembrey ME, Serjeant GR, et al. Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin. Br J Haematol 1980; 45:431.</a></li><li><a class="nounderline abstract_t">Brittenham G, Lozoff B, Harris JW, et al. Sickle cell anemia and trait in southern India: further studies. Am J Hematol 1979; 6:107.</a></li><li><a class="nounderline abstract_t">Diop S, Thiam D, Cisse M, et al. New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal. Hematol Cell Ther 1999; 41:217.</a></li><li><a class="nounderline abstract_t">Fabry ME, Suzuka SM, Weinberg RS, et al. Second generation knockout sickle mice: the effect of HbF. Blood 2001; 97:410.</a></li><li><a class="nounderline abstract_t">Pule GD, Mowla S, Novitzky N, et al. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol 2015; 8:669.</a></li><li><a class="nounderline abstract_t">Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111:231.</a></li><li><a class="nounderline abstract_t">Costa FC, da Cunha AF, Fattori A, et al. Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anaemia. Br J Haematol 2007; 136:333.</a></li><li><a class="nounderline abstract_t">Flanagan JM, Steward S, Howard TA, et al. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol 2012; 157:240.</a></li><li><a class="nounderline abstract_t">Zhu J, Chin K, Aerbajinai W, et al. Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression. Blood 2014; 124:1146.</a></li><li><a class="nounderline abstract_t">Green NS. A step forward back to (induced) fetal. Blood 2014; 124:993.</a></li><li><a class="nounderline abstract_t">Xu J, Zimmer DB. Differential regulation of A gamma and G gamma fetal hemoglobin mRNA levels by hydroxyurea and butyrate. Exp Hematol 1998; 26:265.</a></li><li><a class="nounderline abstract_t">Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002; 116:436.</a></li><li><a class="nounderline abstract_t">Nahavandi M, Tavakkoli F, Wyche MQ, et al. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002; 119:855.</a></li><li><a class="nounderline abstract_t">Iyamu EW, Cecil R, Parkin L, et al. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Br J Haematol 2005; 131:389.</a></li><li><a class="nounderline abstract_t">Cokic VP, Beleslin-Cokic BB, Tomic M, et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006; 108:184.</a></li><li><a class="nounderline abstract_t">Pacelli R, Taira J, Cook JA, et al. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 1996; 347:900.</a></li><li><a class="nounderline abstract_t">Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142:126.</a></li><li><a class="nounderline abstract_t">Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996; 88:4701.</a></li><li><a class="nounderline abstract_t">Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109:322.</a></li><li><a class="nounderline abstract_t">Bartolucci P, Chaar V, Picot J, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood 2010; 116:2152.</a></li><li><a class="nounderline abstract_t">Orringer EP, Blythe DS, Johnson AE, et al. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 1991; 78:212.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol 1997; 98:838.</a></li><li><a class="nounderline abstract_t">Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300.</a></li><li><a class="nounderline abstract_t">Kasschau MR, Barabino GA, Bridges KR, Golan DE. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996; 87:771.</a></li><li><a class="nounderline abstract_t">Benkerrou M, Delarche C, Brahimi L, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002; 99:2297.</a></li><li><a class="nounderline abstract_t">Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75:300.</a></li><li><a class="nounderline abstract_t">Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002; 99:10.</a></li><li><a class="nounderline abstract_t">Yates AM, Dedeken L, Smeltzer MP, et al. Hydroxyurea treatment of children with hemoglobin SC disease. Pediatr Blood Cancer 2013; 60:323.</a></li><li><a class="nounderline abstract_t">Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol 2016; 91:238.</a></li><li><a class="nounderline abstract_t">Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932.</a></li><li><a class="nounderline abstract_t">Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood 2014; 124:3850.</a></li><li><a class="nounderline abstract_t">Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 2020; 4:1554.</a></li><li class="breakAll">http://portal.criticalimpact.com/user/25984/files/ASH_Design_2018-10-09_WEB.pdf (Accessed on January 02, 2019).</li><li class="breakAll">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm (Accessed on January 04, 2019).</li><li><a class="nounderline abstract_t">Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645.</a></li><li><a class="nounderline abstract_t">Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403.</a></li><li><a class="nounderline abstract_t">Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354.</a></li><li><a class="nounderline abstract_t">Lobo CL, Pinto JF, Nascimento EM, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013; 161:852.</a></li><li><a class="nounderline abstract_t">Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148:939.</a></li><li><a class="nounderline abstract_t">Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122:1332.</a></li><li><a class="nounderline abstract_t">Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.</a></li><li><a class="nounderline abstract_t">Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120:4304.</a></li><li><a class="nounderline abstract_t">Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001; 139:790.</a></li><li><a class="nounderline abstract_t">Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97:3628.</a></li><li><a class="nounderline abstract_t">Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005; 105:2685.</a></li><li><a class="nounderline abstract_t">Ghafuri DL, Chaturvedi S, Rodeghier M, et al. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.</a></li><li><a class="nounderline abstract_t">Wang W, Brugnara C, Snyder C, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol 2011; 152:771.</a></li><li><a class="nounderline abstract_t">Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood 2017; 130:2585.</a></li><li><a class="nounderline abstract_t">Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med 2019; 380:121.</a></li><li><a class="nounderline abstract_t">John CC, Opoka RO, Latham TS, et al. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med 2020; 382:2524.</a></li><li><a class="nounderline abstract_t">Olupot-Olupot P, Tomlinson G, Williams TN, et al. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood 2023; 141:1402.</a></li><li><a class="nounderline abstract_t">Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol 2011; 33:251.</a></li><li><a class="nounderline abstract_t">Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64:26.</a></li><li><a class="nounderline abstract_t">Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 2013; 132:677.</a></li><li><a class="nounderline abstract_t">Heitzer AM, Longoria J, Okhomina V, et al. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. Br J Haematol 2021; 195:256.</a></li><li><a class="nounderline abstract_t">Steinberg MH. Sickle cell disease and hydroxyurea: the good, the bad, and the future (editorial). Blood 2005; 105:441.</a></li><li><a class="nounderline abstract_t">Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005; 79:107.</a></li><li><a class="nounderline abstract_t">Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86:273.</a></li><li><a class="nounderline abstract_t">Haywood C Jr, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol 2011; 86:85.</a></li><li><a class="nounderline abstract_t">Reeves SL, Jary HK, Gondhi JP, et al. Hydroxyurea use among children with sickle cell anemia. Pediatr Blood Cancer 2019; 66:e27721.</a></li><li><a class="nounderline abstract_t">Brousseau DC, Richardson T, Hall M, et al. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Stettler N, McKiernan CM, Melin CQ, et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA 2015; 313:1671.</a></li><li><a class="nounderline abstract_t">Tang AY, Zhou M, Maillis AN, et al. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. Pediatr Blood Cancer 2023; 70:e30152.</a></li><li><a class="nounderline abstract_t">Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol 2010; 3:255.</a></li><li class="breakAll">https://www.drugs.com/price-guide/siklos (Accessed on September 21, 2020).</li><li><a class="nounderline abstract_t">Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:1550.</a></li><li><a class="nounderline abstract_t">Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004; 26:179.</a></li><li class="breakAll">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm (Accessed on April 25, 2019).</li><li><a class="nounderline abstract_t">McGann PT, Niss O, Dong M, et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol 2019; 94:871.</a></li><li><a class="nounderline abstract_t">George A, Dinu B, Estrada N, et al. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. Am J Hematol 2020; 95:E242.</a></li><li><a class="nounderline abstract_t">Haddy TB, Castro O. Overt iron deficiency in sickle cell disease. Arch Intern Med 1982; 142:1621.</a></li><li><a class="nounderline abstract_t">Saraf S, Farooqui M, Infusino G, et al. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. Br J Haematol 2011; 153:386.</a></li><li><a class="nounderline abstract_t">Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 2015; 169:746.</a></li><li><a class="nounderline abstract_t">Hankins JS, Penkert RR, Lavoie P, et al. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med (Maywood) 2016; 241:749.</a></li><li><a class="nounderline abstract_t">Smaldone A, Findley S, Manwani D, et al. HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease. J Pediatr 2018; 197:177.</a></li><li><a class="nounderline abstract_t">Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics 2014; 134:465.</a></li><li><a class="nounderline abstract_t">Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics 2014; 134:686.</a></li><li class="breakAll">https://www.abbottpointofcare.com/download?docUri=/technical-library/static-assets/technical-documentation/714183-00Y.pdf (Accessed on November 04, 2016).</li><li class="breakAll">FDA drug prescription information for SIKLOS (hydroxyurea) tablets. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208843s004lbl.pdf (Accessed on November 29, 2023).</li><li><a class="nounderline abstract_t">DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. Expert Rev Hematol 2014; 7:767.</a></li><li><a class="nounderline abstract_t">Smith-Whitley K. Reproductive issues in sickle cell disease. Blood 2014; 124:3538.</a></li><li><a class="nounderline abstract_t">Joseph L, Jean C, Manceau S, et al. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease. Blood 2021; 137:826.</a></li><li><a class="nounderline abstract_t">Gille AS, Pondarré C, Dalle JH, et al. Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease. Blood 2021; 137:856.</a></li><li><a class="nounderline abstract_t">Berthaut I, Bachir D, Kotti S, et al. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood 2017; 130:2354.</a></li><li><a class="nounderline abstract_t">Stukenborg JB, Alves-Lopes JP, Kurek M, et al. Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy. Hum Reprod 2018; 33:1677.</a></li><li><a class="nounderline abstract_t">Pecker LH, Hussain S, Christianson MS, Lanzkron S. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. Br J Haematol 2020; 191:880.</a></li><li><a class="nounderline abstract_t">Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039.</a></li><li><a class="nounderline abstract_t">McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol 2011; 154:134.</a></li><li><a class="nounderline abstract_t">Brunson A, Keegan THM, Bang H, et al. Increased risk of leukemia among sickle cell disease patients in California. Blood 2017; 130:1597.</a></li><li><a class="nounderline abstract_t">Liem RI, Lanzkron S, D Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv 2019; 3:3867.</a></li><li><a class="nounderline abstract_t">Peterson CM, Graziano JH, de Ciutiis A, et al. Iron metabolism, sickle cell disease, and response to cyanate. Blood 1975; 46:583.</a></li></ol></div><div id="topicVersionRevision">Topic 7071 Version 83.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26366626" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hydroxyurea therapy for sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27869662" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Cell Killing Mechanisms of Hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28159390" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367739" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hydroxyurea for the treatment of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1695325" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of sickle cell anemia with hydroxyurea and erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861353" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effect of fetal hemoglobin on the survival characteristics of sickle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313243" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757007" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1690857" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28913922" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/619731" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6158984" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474571" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sickle cell anemia and trait in southern India: further studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651122" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11154217" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Second generation knockout sickle mice: the effect of HbF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26327494" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17156400" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360576" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24914133" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulateγ-globin expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124783" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A step forward back to (induced) fetal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502623" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Differential regulation of A gamma and G gamma fetal hemoglobin mRNA levels by hydroxyurea and butyrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841449" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437671" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225659" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16527893" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622413" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hydroxyurea reacts with heme proteins to generate nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422994" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977264" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10848818" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566895" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1712641" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326175" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cellular effects of hydroxyurea in Hb SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223921" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : How I use hydroxyurea to treat young patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555502" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adhesion of sickle neutrophils and erythrocytes to fibronectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895759" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8982148" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756146" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949140" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hydroxyurea treatment of children with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26615793" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of hydroxyurea treatment for patients with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458271" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25287707" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Update on the use of hydroxyurea therapy in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672732" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513116" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903897" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590693" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458272" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047254" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21571150" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22915643" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of hydroxyurea on clinical events in the BABY HUG trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743503" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369660" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Five years of experience with hydroxyurea in children and young adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15604217" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035747" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715639" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21275961" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29051184" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30501550" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32579813" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375125" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21516020" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815784" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999955" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34272726" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sickle cell disease and hydroxyurea: the good, the bad, and the future (editorial)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15929107" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328441" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21117058" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900800" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hydroxyurea use among children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31227564" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25919532" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36579749" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21082977" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21082977" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477679" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125610" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Chemical and functional analysis of hydroxyurea oral solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125610" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Chemical and functional analysis of hydroxyurea oral solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31106898" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32472611" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7114979" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Overt iron deficiency in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418176" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753472" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940953" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29571930" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157002" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hydroxyurea and growth in young children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180279" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Immunologic effects of hydroxyurea in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180279" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Immunologic effects of hydroxyurea in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180279" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Immunologic effects of hydroxyurea in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242414" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472967" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Reproductive issues in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32976551" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259585" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972009" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30052981" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712966" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630791" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21542824" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830890" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Increased risk of leukemia among sickle cell disease patients in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794601" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1174692" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Iron metabolism, sickle cell disease, and response to cyanate.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
